Cadence Capital Management LLC reduced its stake in Eli Lilly and Co (NYSE:LLY) by 2.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 93,600 shares of the company’s stock after selling 2,065 shares during the period. Cadence Capital Management LLC’s holdings in Eli Lilly and were worth $7,905,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the company. Sfmg LLC grew its position in Eli Lilly and by 0.5% in the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after purchasing an additional 20 shares in the last quarter. Jackson Grant Investment Advisers Inc. grew its position in Eli Lilly and by 0.7% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after purchasing an additional 24 shares in the last quarter. YorkBridge Wealth Partners LLC boosted its stake in Eli Lilly and by 0.8% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock valued at $265,000 after acquiring an additional 24 shares during the last quarter. BSW Wealth Partners boosted its stake in Eli Lilly and by 0.6% in the second quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock valued at $393,000 after acquiring an additional 27 shares during the last quarter. Finally, Pathstone Family Office LLC boosted its stake in Eli Lilly and by 100.0% in the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after acquiring an additional 29 shares during the last quarter. 76.20% of the stock is owned by institutional investors.
A number of research analysts have weighed in on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, October 24th. Berenberg Bank reiterated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research note on Thursday, October 26th. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. Finally, Leerink Swann boosted their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $92.02.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The firm had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. During the same quarter in the prior year, the firm earned $0.95 EPS. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. analysts forecast that Eli Lilly and Co will post 4.88 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.92%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently -1,040.00%.
In other Eli Lilly and news, SVP Susan Mahony sold 36,585 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the sale, the senior vice president now owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the sale, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 259,610 shares of company stock worth $22,727,406. 0.20% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.